Dose-Response Between Serum Prealbumin and All-Cause Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma.
all-cause mortality
dose–response relationship
hepatocellular carcinoma
prognosis
serum prealbumin
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
08
2020
accepted:
25
11
2020
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
The relationship between serum prealbumin and the risk of all-cause mortality after hepatectomy in patients with hepatocellular carcinoma (HCC) needs to be evaluated. We conducted a retrospective study. A Cox proportional hazards regression model was used to adjust for potential confounders. Prealbumin level was transformed by Z-scores and categorized into quartiles (Q1: <147 mg/L, Q2: 147-194 mg/L, Q3: 194-239 mg/L, Q4: >239 mg/L). We assessed the dose-response relationship between serum prealbumin and the risk of all-cause mortality using a restricted cubic spline model. Data were included from 2,022 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital in China between January 2006 and January 2016. The adjusted hazard ratios (HRs) for increasing quartiles of serum prealbumin were 0.78 [95% confidence interval (CI): 0.64-0.95] for Q2, 0.66 (0.53-0.81) for Q3, and 0.51 (0.41-0.64) for Q4 in the Cox model (all P < 0.001). Serum prealbumin showed an L-shaped, non-linear dose-response relationship with the risk of all-cause mortality (P < 0.001). Among patients whose serum prealbumin was below 250 mg/L, risk of all-cause mortality decreased by 27% (95% CI: 18-36%) per increase of one standard deviation (69.8 mg/L) in serum prealbumin. Levels of serum prealbumin under 250 mg/L may be considered dangerous with respect to all-cause mortality after hepatectomy in HCC patients. Serum prealbumin may be useful as a prognostic marker in HCC patients undergoing hepatectomy.
Sections du résumé
BACKGROUND
BACKGROUND
The relationship between serum prealbumin and the risk of all-cause mortality after hepatectomy in patients with hepatocellular carcinoma (HCC) needs to be evaluated.
METHODS
METHODS
We conducted a retrospective study. A Cox proportional hazards regression model was used to adjust for potential confounders. Prealbumin level was transformed by Z-scores and categorized into quartiles (Q1: <147 mg/L, Q2: 147-194 mg/L, Q3: 194-239 mg/L, Q4: >239 mg/L). We assessed the dose-response relationship between serum prealbumin and the risk of all-cause mortality using a restricted cubic spline model.
RESULTS
RESULTS
Data were included from 2,022 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital in China between January 2006 and January 2016. The adjusted hazard ratios (HRs) for increasing quartiles of serum prealbumin were 0.78 [95% confidence interval (CI): 0.64-0.95] for Q2, 0.66 (0.53-0.81) for Q3, and 0.51 (0.41-0.64) for Q4 in the Cox model (all P < 0.001). Serum prealbumin showed an L-shaped, non-linear dose-response relationship with the risk of all-cause mortality (P < 0.001). Among patients whose serum prealbumin was below 250 mg/L, risk of all-cause mortality decreased by 27% (95% CI: 18-36%) per increase of one standard deviation (69.8 mg/L) in serum prealbumin.
CONCLUSIONS
CONCLUSIONS
Levels of serum prealbumin under 250 mg/L may be considered dangerous with respect to all-cause mortality after hepatectomy in HCC patients. Serum prealbumin may be useful as a prognostic marker in HCC patients undergoing hepatectomy.
Identifiants
pubmed: 33505912
doi: 10.3389/fonc.2020.596691
pmc: PMC7830881
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596691Informations de copyright
Copyright © 2021 Huo, Liu, Deng, Liang, Gong, Qi, You, Xiang, Li, Ma and Zhong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
HPB (Oxford). 2017 Aug;19(8):695-705
pubmed: 28479010
Nursing. 2005 May;35(5):70-1
pubmed: 15879981
Bull Cancer. 2008 Dec;95(12):1219-25
pubmed: 19091657
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Adv Skin Wound Care. 2001 Sep-Oct;14(5):235-6
pubmed: 11905970
Am J Epidemiol. 1992 Aug 15;136(4):464-74
pubmed: 1415166
Dig Surg. 2018;35(6):520-531
pubmed: 29342456
World J Surg. 2012 Dec;36(12):2853-7
pubmed: 22948197
J Appl Physiol (1985). 1989 Jul;67(1):390-6
pubmed: 2759968
HPB (Oxford). 2019 Feb;21(2):157-166
pubmed: 30082212
Medicine (Baltimore). 2016 Feb;95(5):e2722
pubmed: 26844516
Nutr Cancer. 2014;66(3):517-22
pubmed: 24033366
Comput Methods Programs Biomed. 1986 Aug;23(1):53-5
pubmed: 3638186
Int Immunopharmacol. 2017 Oct;51:1-8
pubmed: 28759808
J Surg Oncol. 2019 May;119(6):794-800
pubmed: 30648280
Am Fam Physician. 2002 Apr 15;65(8):1575-8
pubmed: 11989633
Clin Chem. 2006 Dec;52(12):2281-5
pubmed: 17068165
J Cancer. 2019 Jun 2;10(13):3006-3011
pubmed: 31281477
J Visc Surg. 2015 Nov;152(5):297-304
pubmed: 26476674
Pancreatology. 2015 Mar-Apr;15(2):145-50
pubmed: 25641673
Am J Epidemiol. 2017 Jun 15;185(12):1304-1316
pubmed: 28472215
Genet Mol Res. 2015 Jun 29;14(2):7130-5
pubmed: 26125923
Ann Surg. 2014 Oct;260(4):650-6; discussion 656-8
pubmed: 25203882
Stat Med. 2010 Apr 30;29(9):1037-57
pubmed: 20087875
Ann Surg. 2014 Aug;260(2):329-40
pubmed: 24096763
Ann Surg. 2015 Jun;261(6):1173-83
pubmed: 24950264
J Gastrointest Surg. 2017 Dec;21(12):2033-2038
pubmed: 28785936
Liver Transpl. 2006 Jun;12(6):966-71
pubmed: 16598792
Gynecol Obstet Invest. 1994;37(2):135-40
pubmed: 8150370
Gut. 2015 Mar;64(3):520-1
pubmed: 25187522
Gastroenterol Res Pract. 2016;2016:4686189
pubmed: 26904109
Swiss Med Wkly. 2014 Jan 22;144:w13900
pubmed: 24452307
Int J Surg. 2018 Jul;55:73-80
pubmed: 29787804
Nutrition. 1996 Apr;12(4):255-9
pubmed: 8862531